Previous 10 | Next 10 |
– Prescription Drug User Fee Act (PDUFA) goal date extended by three months to September 23, 2021 – WEST CHESTER, Pa., May 28, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medi...
WEST CHESTER, Pa., May 26, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO, ...
Fate's early stage data look promising: JefferiesFate Therapeutics (FATE) shares shed ~1.4% after the company announced data from an early stage leukemia trial for its natural killer ((NK)) cell programs.Fate has lost ~21.3% in the year so far and noting that data looked promising and have de...
scPharmaceuticals (SCPH) received a second Complete Response Letter (CRL) on Furoscix rather than an FDA approval in December of 2020. The issues in the CRL are being addressed. The subcutaneous, home delivery of tried-and-true drugs offers a convenient and compelling value propositio...
WEST CHESTER, Pa., May 12, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO, ...
Verrica Pharmaceuticals (VRCA): Q1 GAAP EPS of -$0.04 beats by $0.32.Revenue of $12MPress Release For further details see: Verrica Pharmaceuticals EPS beats by $0.32
– Expanded commercial team in preparation for potential FDA approval of VP-102 for the treatment of molluscum, which has been assigned a PDUFA goal date of June 23, 2021 – – Raised approximately $30 million, before offering expenses, in an underwritten ...
WEST CHESTER, Pa., April 06, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO...
WEST CHESTER, Pa., March 29, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (NASDAQ: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Gary Goldenberg, M.D., Verrica’s Chief Medica...
WEST CHESTER, Pa., March 22, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (NASDAQ: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the pricing of its underwritten public offering of 2,033,...
News, Short Squeeze, Breakout and More Instantly...
Verrica Pharmaceuticals Inc. Company Name:
VRCA Stock Symbol:
NASDAQ Market:
Verrica Pharmaceuticals Inc. Website:
- Dormer Labs has discontinued the sale of all cantharidin-containing products into the United States - YCANTH is the only commercially available, FDA approved therapy for molluscum contagiosum and is clinically proven to be safe and effective WEST CHESTER, Pa., July 01, 202...
WEST CHESTER, Pa., May 30, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Pr...
Global pivotal Phase 3 clinical trial would be conducted jointly by Verrica and Torii Pharmaceutical; trial expected to begin in the 1 st half of 2025 Amendment should benefit both parties from a cost and time to market standpoint; funding structure is expected to have a min...